Dr. David Young Healy Jr., M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 160 Heritage Way, Suite 201, Kalispell, MT 59901 Phone: 406-752-8330 Fax: 406-752-8412 |
Kent Keele, DO Otolaryngology - Facial Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 160 Heritage Way, Kalispell, MT 59901 Phone: 406-752-8330 |
Kyle J Tubbs, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 160 Heritage Way, Kalispell, MT 59901 Phone: 406-752-8330 |
Mr. Karl Martin Oehrtman, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 160 Heritage Way, Kalispell, MT 59901 Phone: 406-752-8330 Fax: 406-752-8412 |
Mr. Jeffrey William Bartels, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 160 Heritage Way, Kalispell, MT 59901 Phone: 406-752-8330 Fax: 406-752-8412 |
John A Schvaneveldt, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 160 Heritage Way, Kalispell, MT 59901 Phone: 406-752-8330 Fax: 406-752-8412 |
Dr. Mitchell Jay Ramsey, MD Otolaryngology - Otology & Neurotology Medicare: Accepting Medicare Assignments Practice Location: 160 Heritage Way, Suite 201, Kalispell, MT 59901 Phone: 406-752-8330 Fax: 406-752-8412 |
News Archive
DUSA Pharmaceuticals, Inc.®, a specialty pharmaceutical company focused on dermatology, will unveil an ergonomically enhanced BLU-U® Blue Light Photodynamic Therapy Illuminator at this year's American Academy of Dermatology meeting in Miami, Florida, March 5-9. BLU-U, in conjunction with the Levulan® Kerastick® topical treatment, is an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform.
Forty percent of U.S. adults intend to change their holiday plans due to the risk of being exposed to the H1N1 flu virus, according to a nationwide survey commissioned by JohnsonDiversey, a global leader in the commercial cleaning and sanitizing industry.
Computed tomography of the head uses special X-ray equipment to help assess head injuries, dizziness, and other symptoms of the brain.
Mesoblast Limited today announced that it has entered into a partnership with Cartherics Pty Ltd to develop allogeneic ‘off-the-shelf' CAR-T cells armed with multiple targeting receptors for use in solid cancers. Off the shelf CAR-T therapies have the potential to reduce costs dramatically and open up this very effective treatment to millions of cancer patients across the world.
› Verified 2 days ago